BEDFORD, Mass.—Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of therapies for diseases and conditions of the eye, has announced board of directors and leadership updates. Pravin U. Dugel, MD has been named executive chairman, and Jeffrey S. Heier, MD, Peter K. Kaiser, MD, and Sanjay Nayak, MBBS, PhD have been appointed to the ocular management team as chief scientific officer, medical director, and chief strategy officer, respectively. Read More